VitalDose® EVA excipients - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Participate in the VitalDose excipient discussion. Ken Anderson of Celanese shares insights into EVA excipients technology and invites you to ask questions about one of the most versatile polymers utilized in the pharmaceutical industry.

Are you in search of routes of administration that can breathe new life into your expiring drug patents? Want to learn more about excipients technology for use in novel controlled released products? Find answers to these questions and more at the recently launched blog – VitalDose.com/blog – where Celanese EVA Performance Polymers technical leader, Ken Anderson, Ph.D. will provide regular updates and summaries on the latest research pertaining to EVA excipients.

In participating in the new VitalDose blog, you will learn:

  • The latest news in VitalDose ethylene vinyl acetate (EVA) excipients
  • Technical data on this technology and its applications
  • Solutions to formulation challenges.

EVA polymers have been used for many years in a variety of pharmaceutical and medical device products.

Tailor the dosing and delivery of your API

  • Formulation design versatility
  • Customizable delivery and release profiles
  • Manufacturing process versatility
  • Multiple routes of administration

Learn more about EVA polymers at the VitalDose.com website or e-mail us at VitalDose@Celanese.com.

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
FindPharma Custom Search

Click here